Shares of Senseonics Holdings, Inc. (SENS) surged 11.52% in after-hours trading on Wednesday, following the company's announcement of operational and financial updates, including the successful launch of its Eversense 365 continuous glucose monitoring (CGM) system and a positive outlook for 2025.
Senseonics reported preliminary unaudited fourth-quarter revenue of approximately $8.3 million and full-year 2024 revenue of around $22.5 million. The company highlighted several key achievements in 2024, including receiving FDA approval for and launching the Eversense 365 CGM system in collaboration with its commercial partner, Ascensia.
The launch of Eversense 365, which can monitor glucose levels for up to 365 days with a single implantable sensor, has been met with strong early interest. Senseonics noted a doubling of direct-to-consumer leads in Q4 compared to Q3, a record high of approximately 600 new patient shipments in December, a 49% increase in patients switching from competitive CGM systems, and a 118% surge in physician referrals since the launch.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。